An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Cetuximab; Cisplatin; Fluorouracil
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 651
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 Jul 2018 Planned End Date changed from 1 Mar 2020 to 15 Aug 2025.
    • 03 Jul 2018 Planned primary completion date changed from 14 Feb 2019 to 14 Aug 2020.
    • 12 Feb 2018 Planned End Date changed from 15 Dec 2020 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top